+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2020

  • PDF Icon

    Drug Pipelines

  • 57 Pages
  • September 2020
  • Region: Global
  • Global Markets Direct
  • ID: 5174743
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Proliferative Diabetic Retinopathy - Pipeline Review, H2 2020, provides an overview of the Proliferative Diabetic Retinopathy (Metabolic Disorders) pipeline landscape.

Proliferative diabetic retinopathy (PDR) is the most severe type of diabetic retinopathy. Proliferative diabetic retinopathy occurs where fragile new blood vessels form on the surface of the retina over time. These abnormal vessels can bleed or develop scar tissue causing severe loss of sight. Predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use. Symptoms include spots or dark strings floating in vision, vision loss, fluctuating vision, blurred vision and difficulty with color perception.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Proliferative Diabetic Retinopathy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Proliferative Diabetic Retinopathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Proliferative Diabetic Retinopathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Proliferative Diabetic Retinopathy (PDR) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 2 and 3 respectively.

Proliferative Diabetic Retinopathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Proliferative Diabetic Retinopathy (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Proliferative Diabetic Retinopathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Proliferative Diabetic Retinopathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Proliferative Diabetic Retinopathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Proliferative Diabetic Retinopathy (Metabolic Disorders)

Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Proliferative Diabetic Retinopathy (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Proliferative Diabetic Retinopathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction
  • Report Coverage

Proliferative Diabetic Retinopathy (PDR) - Overview
Proliferative Diabetic Retinopathy (PDR) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies

Proliferative Diabetic Retinopathy (PDR) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type

Proliferative Diabetic Retinopathy (PDR) - Companies Involved in Therapeutics Development
  • Aerie Pharmaceuticals Inc
  • Antisense Therapeutics Ltd
  • Boehringer Ingelheim International GmbH
  • Generium
  • Kubota Vision Inc
  • Kuur Therapeutics Ltd
  • Oxurion NV
  • Protheragen Inc
  • Ribomic Inc

Proliferative Diabetic Retinopathy (PDR) - Drug Profiles
AR-13503 SR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

atesidorsen sodium - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

BI-764524 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

brolucizumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

emixustat hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Monoclonal Antibody to Inhibit SCG3 for Metabolic Disorders, Oncology and Ophthalmology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

ranibizumab biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

RBM-008 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

THR-687 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Proliferative Diabetic Retinopathy (PDR) - Dormant Projects
Proliferative Diabetic Retinopathy (PDR) - Product Development Milestones
  • Featured News & Press Releases
  • May 08, 2016: Acucela Initiates Phase 2 Clinical Trial Addressing Proliferative Diabetic Retinopathy

Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact
  • Disclaimer

List of Tables
  • Number of Products under Development for Proliferative Diabetic Retinopathy (PDR), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Proliferative Diabetic Retinopathy (PDR) - Pipeline by Aerie Pharmaceuticals Inc, H2 2020
  • Proliferative Diabetic Retinopathy (PDR) - Pipeline by Antisense Therapeutics Ltd, H2 2020
  • Proliferative Diabetic Retinopathy (PDR) - Pipeline by Boehringer Ingelheim International GmbH, H2 2020
  • Proliferative Diabetic Retinopathy (PDR) - Pipeline by Generium, H2 2020
  • Proliferative Diabetic Retinopathy (PDR) - Pipeline by Kubota Vision Inc, H2 2020
  • Proliferative Diabetic Retinopathy (PDR) - Pipeline by Kuur Therapeutics Ltd, H2 2020
  • Proliferative Diabetic Retinopathy (PDR) - Pipeline by Oxurion NV, H2 2020
  • Proliferative Diabetic Retinopathy (PDR) - Pipeline by Protheragen Inc, H2 2020
  • Proliferative Diabetic Retinopathy (PDR) - Pipeline by Ribomic Inc, H2 2020
  • Proliferative Diabetic Retinopathy (PDR) - Dormant Projects, H2 2020

List of Figures
  • Number of Products under Development for Proliferative Diabetic Retinopathy (PDR), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Aerie Pharmaceuticals Inc
  • Antisense Therapeutics Ltd
  • Boehringer Ingelheim International GmbH
  • Generium
  • Kubota Vision Inc
  • Kuur Therapeutics Ltd
  • Oxurion NV
  • Protheragen Inc
  • Ribomic Inc